FDA approves first treatment for certain BCG-unresponsive bladder cancer patients

FDA approval · Gulf Coast Media · 2026-10-29. Number 2 in the UrologyWatch Top 5 for October 30, 2026.

The FDA approved a new agent for a subset of patients with BCG-unresponsive non-muscle-invasive bladder cancer, per the report. The article does not specify the drug name or trial data in detail.

Why it matters: Adds another option for a population with historically limited salvage therapies after BCG failure.

Source: Gulf Coast Media

The full October 30, 2026 edition · Today's urology news